Navigation Links
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Date:1/3/2008

six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

About VYVANSE

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if your child develops symptoms that suggest heart problems, such as chest pain or fainting.

VYVANSE should not be taken if your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking VYVANSE if your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if your child develops any of these conditions or symptoms while taking VYVANSE.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studie
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
2. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
3. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
4. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
5. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
6. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
7. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
8. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
9. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 iLab Solutions, the ... appointment of Siri Bryant as the new Director of ... of Core Implementations. These two new leadership positions were ... service by ensuring that iLab continues to meet the ... last four years, iLab has been deployed at over ...
(Date:12/19/2014)... 19, 2014 The empty capsules ... rising ageing population and technological innovations in the ... industries are catalysing the growth of the empty ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , The ... as new entrants/smaller firms to gauge the pulse ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will grow moderately through 2023 as the aging population, ... of dental biomaterials all spur procedure volumes. Growth will ... China and India ... within reach for a larger proportion of the population. ...
(Date:12/19/2014)... 18, 2014   ISN has released its ... Indicators publication series. With data aggregated from ... in 2013 within its online contractor management platform, ISNetworld, ... performance indicator (KPI) statistics. The ... publication is available in two industry specific volumes: ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3
... 29 ImQuest BioSciences and Arisyn Therapeutics jointly ... strategic drug development partnership to provide support necessary ... the treatment of infectious disease and cancer. Arisyn ... of inhibitors with demonstrated preclinical efficacy against HIV, ...
... - Strong Focus on the Markets of ... General Meeting Passes Dividend of EUR0.40 per Share , ... an unchanged,dividend of EUR0.40 per share following the record year in ... year 2008 with record results.,Gerresheimer achieved sales of EUR1.06 billion (prior ...
... Survival and Biomarker Data for Ipilimumab to be Presented ... MEDX ) announced today that the following clinical ... well as for an anti-PD-1 antibody for cancer treatment, ... at the Annual Meeting of the American Society of ...
Cached Biology Technology:ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs 22008 a Record Year for Gerresheimer 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 4
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... The first stage of the U.S. Department of Defense-funded ... in the transmission of infectious pathogens has been completed ... session at the Interscience Conference on Antimicrobial Agents and ... The data presented describe the first results of ...
... Darrel Jenerette, a landscape ecologist at UC Riverside, is ... will be investigating human vulnerability to deadly heat exposure. ... heat island" a metropolitan area that is much warmer ... risks, as well as how human decisions lead to this ...
... division mechanism has been discovered in a microorganism that thrives ... into key processes in human cells, and in a better ... The study is published today in the online version the ... research group at the Department of Molecular Evolution at Uppsala ...
Cached Biology News:UC Riverside scientist to explore how vegetation affects urban heat islands 2New cell division mechanism discovered 2